The U.S. drug regulator asked Pfizer, Eli Lilly and AbbVie to include information about the risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors.

A study published in the Journal of the American Medical Association by Belgium researchers comparing the Moderna and Pfizer-BioNTech Covid-19 vaccines found that the Moderna jabs generated twice the antibodies as the Pfizer-BioNTech vaccine.

Roche

Roche Holding AG decided to withdraw the company’s immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States, the drugmaker said on Aug. 26 following a consultation with the Food and Drug Administration.

Early data from a Phase III study of Brii Biosciences’ monoclonal antibody combination therapy for Covid-19 is showing significant promise.

A new study may help explain why mRNA vaccines by Pfizer/BioNTech and Moderna are more effective at preventing hospitalizations and deaths than they are at preventing infection. In another study, preliminary data suggests certain cancer drugs may help protect patients with malignancies from being infected with the new coronavirus.

More studies into vaccinated populations show that although antibody responses drop months after vaccination against Covid-19, they still dramatically protect against severe disease and hospitalization. Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant.

Theravance announced that the diversified biopharmaceutical company’s oral drug candidate for the possible treatment of ulcerative colitis failed to meet the primary endpoint of a Phase IIb study.

The Food and Drug Administration on Aug. 23 approved Cara Therapeutics’ drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making Korsuva the first therapy for the ailment in the United States.

“You are not a horse. You are not a cow. Seriously, y’all. Stop it.” This is the Food and Drug Administration’s (FDA) tweeted advice to Americans seeking out alternative, unapproved treatments for Covid-19.

Pfizer is buying Toronto and Cambridge, Massachusetts-based Trillium Therapeutics in a deal worth $2.26 billion. Trillium focuses on developing a new set of checkpoint inhibitors to treat cancer.